Business
Hikma receives FDA approval for generic Vascepa®
Hikma receives FDA approval for generic Vascepa®.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n RNS Number : 7388N\n Hikma Pharmaceuticals Plc\n 22 May 2020\n \n \n \n \n \n London, \n \n \n May 22, 2020\n \n \n - \n Hikma Pharmaceuticals PLC\n (Hikma), the multinational generic pharmaceutical company, today announces \n that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1. \n \n \n \n \n \n In March 2020, the \n United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.\n \n \n \n \n \n Brian Hoffmann, President of Generics said, \"The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need.\" \n \n \n \n 1\n \n Vascepa® is a registered trademark of Amarin Pharmaceuticals Ireland Limited.\n \n \n - ENDS -\n \n \n \n \n \n Enquiries \n \n \n Hikma Pharmaceuticals PLC \n \n \n \n \n \n Susan Ringdal\n \n \n EVP, Strategic Planning and Global Affairs\n \n \n \n \n +44 (0)20 7399 2760/ +44 7776 477050\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n Steve Weiss\n \n \n David Belian\n \n \n US Communications and Public Affairs \n \n \n \n \n +1 732 720 2830/ +1 732 788 8279\n \n \n +1 732 720 2814/+1 848 254 4875\n \n \n \n u\n \n \n scommunications\n \n \n @hikma.com\n \n \n \n \n \n \n \n \n \n \n \n \n \n About Hikma\n \n (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P)\n \n \n \n \n \n Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into in...